659 studies found for:    Erythropoietin
Show Display Options
Rank Status Study
1 Active, not recruiting Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Conditions: Anemia;   Chronic Kidney Disease (CKD)
Interventions: Drug: HX575 epoetin alfa;   Drug: US-licensed epoetin alfa
2 Completed Comparison Among Erythropoietin Stimulating Agents
Condition: Anemia of End Stage Renal Disease
Interventions: Drug: Epoetin alpha or beta (Epoetin group);   Drug: Darbepoetin alfa;   Drug: Methoxy polyethylene glycol-epoetin beta
3 Completed A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
Conditions: Chronic Kidney Disease;   Chronic Renal Failure
Interventions: Biological: Epoetin Hospira;   Biological: Epogen (Amgen)
4 Active, not recruiting HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)
Condition: Chronic Kidney Disease
Intervention: Drug: HX575 epoetin alfa (Sandoz)
5 Withdrawn A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies
Condition: Anemia
Intervention: Drug: No intervention
6 Completed
Has Results
Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral Palsy
Condition: Cerebral Palsy
Interventions: Biological: Umbilical Cord Blood Infusion;   Drug: Erythropoietin Injection;   Other: Active Rehabilitation;   Other: Placebo Umbilical Cord Blood;   Other: Placebo Erythropoietin
7 Completed
Has Results
Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy
Condition: Leukemia
Intervention: Drug: Procrit (epoetin alfa)
8 Completed A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa
Condition: Pure Red-cell Aplasia
Intervention: Drug: No intervention
9 Completed
Has Results
An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease
Condition: Anemia
Interventions: Drug: Epoetin alfa 3 times weekly /once weekly;   Drug: Epoetin alfa once weekly;   Drug: Epoetin alfa once every two weeks
10 Completed
Has Results
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
Conditions: Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Leukemia
Intervention: Drug: Procrit
11 Terminated
Has Results
An Observational Study to Predict the Response of Erythropoietin Treatment in Participants With Cancer Related Anemia Receiving Chemotherapy
Condition: Anemia - Cancer Related
Intervention: Drug: Erythropoietin: Observational study
12 Not yet recruiting PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects
Condition: Healthy
Intervention: Drug: Epoetin Alfa
13 Terminated
Has Results
Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa
Condition: Subarachnoid Hemorrhage
Interventions: Drug: Epoetin alfa;   Drug: Saline
14 Withdrawn Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia
Condition: Anemia
Intervention: Drug: Epoetin Alfa plus Iron
15 Not yet recruiting PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects.
Condition: Healthy
Intervention: Drug: Epoetin Alfa
16 Completed Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.
Condition: Chronic Kidney Disease
Intervention: Drug: HX575 recombinant human erythropoietin alfa
17 Completed
Has Results
A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.
Conditions: Renal Failure , Chronic;   Anemia
Interventions: Drug: Epoetin Alfa;   Other: Standard of care
18 Completed Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia
Conditions: Sickle Cell Disease;   Chronic Kidney Disease;   Pulmonary Hypertension
Intervention: Drug: Erythropoietin and Hydroxyurea
19 Completed An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)
Conditions: Anemia;   HIV Infections
Intervention: Drug: Epoetin alfa
20 Unknown  Autoantibodies Against Human Recombinant Erythropoietin in Myelodysplatic Syndrome Patients
Condition: Myelodysplatic Syndrome
Intervention:

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years